Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01716975




Registration number
NCT01716975
Ethics application status
Date submitted
19/10/2012
Date registered
30/10/2012
Date last updated
3/05/2016

Titles & IDs
Public title
Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Scientific title
A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
Secondary ID [1] 0 0
2012-003209-92
Secondary ID [2] 0 0
EVP-6124-016
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Schizophrenia 0 0
Impaired Cognition 0 0
Condition category
Condition code
Mental Health 0 0 0 0
Schizophrenia
Mental Health 0 0 0 0
Other mental health disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - EVP-6124
Treatment: Drugs - Placebo

Placebo comparator: EVP-6124, Placebo - Placebo, Tablet, Once Daily, Day -14 through Day 182

Experimental: EVP-6124, low dose - low dose, Tablet, Once Daily, Day 1 through Day 182

Experimental: EVP-6124, high dose - high dose, Tablet, Once Daily, Day 1 through Day 182


Treatment: Drugs: EVP-6124
Arms 1, 2

Treatment: Drugs: Placebo
Arm 3
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change from Baseline in the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) to Day 182
Timepoint [1] 0 0
Baseline to Day 182 or Early Termination
Primary outcome [2] 0 0
Change from Baseline in the Schizophrenia Cognition Rating Scale (SCoRs) to Day 182
Timepoint [2] 0 0
Baseline to Day 182 or Early Termination
Primary outcome [3] 0 0
Safety and Tolerability of EVP-6124 or Placebo in Subjects with Schizophrenia
Timepoint [3] 0 0
Screening (Day -42 to Day -15) to Day 182 or Early Terminiation
Secondary outcome [1] 0 0
Change from Baseline in the Positive and Negative Symptom Scale (PANSS) to Day 182
Timepoint [1] 0 0
Baseline to Day 182 or Early Termination
Secondary outcome [2] 0 0
Change from Baseline in the Clinical Global Impression-Severity (CGI-S) to Day 182
Timepoint [2] 0 0
Baseline to Day 182 or Early Termination
Secondary outcome [3] 0 0
Change from Baseline in the Clinical Global Impression Change Scale (CGI-C) to Day 182
Timepoint [3] 0 0
Baseline to Day 182 or Early Termination
Secondary outcome [4] 0 0
Change from Baseline in the EuroQOL-5D (EQ-5D) to Day 182
Timepoint [4] 0 0
Baseline to Day 182 or Early Termination

Eligibility
Key inclusion criteria
* Age 18 to 50 years of age, inclusive
* Signed informed consent, indicating that the subject understands the purpose of and procedures required for the study, before the initiation of any study specific procedures. Subjects who are unable to provide informed consent will not be included in the study.
* Resides in a stable living situation, according to the investigator's judgment, and must have an identified informant who should be consistent throughout the study. If possible, the informant should accompany the subject or be available for in person ratings at the screening, baseline (Day 1), and final study visits. In person informant ratings on all relevant study visits are preferred whenever possible. However, if the informant is not available for in person ratings, telephone interview is acceptable. The informant must be available for a telephone interview throughout the study at all visits. As long as both the informant visit and subject visit are within the study visit windows, it is not necessary that they occur on the same day. The informant must interact with the subject at least 2 times a week.
* Diagnosis of Schizophrenia of at least 3 years duration. This diagnosis can be established utilizing the SCID-I, direct clinical assessments, family, informants, and confirmation of diagnosis from clinical sources. These may include medical records, confirmation of diagnosis by treating clinician through telephone contact, or written confirmation from treating clinic. If the listed sources are not available, other sources of diagnostic confirmation may also be acceptable after discussion with the medical monitor.
* Treated with atypical antipsychotic drug (in any approved dosage form) other than Clozapine at a stable dose for at least 8 weeks prior to screening and be clinically stable; the subject must remain clinically stable (in the opinion of the principal investigator) through randomization. The use of up to 2 atypical antipsychotic drugs is permitted, as long as in the opinion of the investigator, the second medication is not required to control treatment-resistant or intractable psychotic symptoms. No subject will be washed off antipsychotic therapy to become eligible for this study.
* Schizophrenia clinical symptom burden severity defined by the following: a Brief Psychiatric Rating Scale (BPRS) Conceptual Disorganization item score = 4; and a BPRS Hallucinatory Behavior item score = 5, or an Unusual Thought Content item score = 5. Either Hallucinatory Behavior or Unusual Thought Content, but not both, may have a score of 6 (but not > 6).
* Simpson-Angus Scale (SAS) total score = 6
* Calgary Depression Scale for Schizophrenia (CDSS) total score = 10
* General health status acceptable for participation in a 26-week clinical study
* Fertile, sexually active subjects (men and women) must use an effective method of contraception during the study
* Fluency (oral and written) in the language in which the standardized tests will be administered
* The ability to refrain from using any tobacco or other nicotine-containing products for at least 30 minutes before any cognitive testing
Minimum age
18 Years
Maximum age
50 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Hospitalization within 12 weeks before screening or during the screening period, or change of antipsychotic medication or dose within 8 weeks before screening or during the screening period.
* Participation in another therapeutic (medication administration) clinical study within the past 2 months.
* Psychiatric hospitalization or incarcerations due to breakthrough symptoms or acute exacerbations for a period of 3 months before screening. Subjects with a recent "social" hospitalization or incarceration may be entered into screening after consultation with the medical monitor
* Likelihood, in the opinion of the investigator, that either the subject or informant will be unable to complete a 26-week study
* Treatment with prohibited antipsychotic drug, and/or treatment with more than 2 permitted antipsychotic drugs. Treatment with a first-generation antipsychotic drug (typical antipsychotic) is prohibited unless it is administered at a low dose after discussion with the medical monitor
* Current treatment with any anticholinergic agent
* Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) criteria met for alcohol abuse within the past 3 months or substance abuse (other than nicotine) within the last 6 months before screening
* Significant suicide risk as defined by 1) suicidal ideation as endorsed on items 4 or 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) within the past year; 2) suicidal behavior detected by the C-SSRS during the past 2 years, or 3) psychiatric interview and examination
* Stroke within 6 months before screening, history of brain tumor, subdural hematoma, or other clinically significant neurological condition, head trauma with loss of consciousness within 12 months before screening
* Monoamine oxidase inhibitor antidepressants or tricyclic medications used in antidepressant doses are excluded. Other antidepressant medications are allowed if the subject has been treated with a stable dose for at least 3 months before screening
* Immunosuppressants, mood stabilizers, chronic use of a sedative hypnotic drug, chronic intake of clinically significant doses of opioid containing analgesics or any current methadone treatment all in the judgment of the investigator may be permitted depending on the circumstance
* Use of Central Nervous System(CNS) stimulants
* Nicotine therapy (including patches), varenicline (Chantix), or similar therapeutic agent within the last six months before screening
* Use of a benzodiazepine medication is allowed if the subject has not had a change in medication or dose for at least 3 months. For subjects prescribed benzodiazepines, short-acting benzodiazepines are to be used whenever possible. Use of longer-acting benzodiazepines may be acceptable if prior authorization is obtained from the medical monitor. When possible, benzodiazepines should not be administered within 3 hours before cognitive testing. The use of more than one sedative-hypnotic medication is not allowed.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/10/2012
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/02/2016
Sample size
Target
Accrual to date
Final
767
Recruitment in Australia
Recruitment state(s)
SA,WA
Recruitment hospital [1] 0 0
- Adelaide
Recruitment hospital [2] 0 0
- Mt. Claremont
Recruitment postcode(s) [1] 0 0
- Adelaide
Recruitment postcode(s) [2] 0 0
- Mt. Claremont
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
Arkansas
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
District of Columbia
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Kansas
Country [9] 0 0
United States of America
State/province [9] 0 0
Louisiana
Country [10] 0 0
United States of America
State/province [10] 0 0
Maryland
Country [11] 0 0
United States of America
State/province [11] 0 0
Massachusetts
Country [12] 0 0
United States of America
State/province [12] 0 0
Missouri
Country [13] 0 0
United States of America
State/province [13] 0 0
Nebraska
Country [14] 0 0
United States of America
State/province [14] 0 0
New Jersey
Country [15] 0 0
United States of America
State/province [15] 0 0
New York
Country [16] 0 0
United States of America
State/province [16] 0 0
North Carolina
Country [17] 0 0
United States of America
State/province [17] 0 0
Ohio
Country [18] 0 0
United States of America
State/province [18] 0 0
Oklahoma
Country [19] 0 0
United States of America
State/province [19] 0 0
Pennsylvania
Country [20] 0 0
United States of America
State/province [20] 0 0
Texas
Country [21] 0 0
United States of America
State/province [21] 0 0
Utah
Country [22] 0 0
United States of America
State/province [22] 0 0
Washington
Country [23] 0 0
Argentina
State/province [23] 0 0
Buenos Aires
Country [24] 0 0
Argentina
State/province [24] 0 0
Santa Fe
Country [25] 0 0
Argentina
State/province [25] 0 0
Caba
Country [26] 0 0
Argentina
State/province [26] 0 0
Mendoza
Country [27] 0 0
Argentina
State/province [27] 0 0
Santiago del Estero
Country [28] 0 0
Brazil
State/province [28] 0 0
BA
Country [29] 0 0
Brazil
State/province [29] 0 0
MG
Country [30] 0 0
Brazil
State/province [30] 0 0
Parana
Country [31] 0 0
Colombia
State/province [31] 0 0
Antioquia
Country [32] 0 0
Colombia
State/province [32] 0 0
Atlantico
Country [33] 0 0
Colombia
State/province [33] 0 0
Risaralda
Country [34] 0 0
Colombia
State/province [34] 0 0
Bogota D.C.
Country [35] 0 0
Italy
State/province [35] 0 0
FL
Country [36] 0 0
Italy
State/province [36] 0 0
MI
Country [37] 0 0
Italy
State/province [37] 0 0
Ban
Country [38] 0 0
Italy
State/province [38] 0 0
Barl
Country [39] 0 0
Italy
State/province [39] 0 0
Catania
Country [40] 0 0
Italy
State/province [40] 0 0
Lucca
Country [41] 0 0
Italy
State/province [41] 0 0
Milano
Country [42] 0 0
Italy
State/province [42] 0 0
Pisa
Country [43] 0 0
Italy
State/province [43] 0 0
Roma
Country [44] 0 0
Mexico
State/province [44] 0 0
Nuevo Leon
Country [45] 0 0
Mexico
State/province [45] 0 0
Mexico, D.F
Country [46] 0 0
Mexico
State/province [46] 0 0
San Luis Potosi
Country [47] 0 0
Poland
State/province [47] 0 0
Belchatow
Country [48] 0 0
Poland
State/province [48] 0 0
Chelmno
Country [49] 0 0
Poland
State/province [49] 0 0
Karakow
Country [50] 0 0
Poland
State/province [50] 0 0
Kielce
Country [51] 0 0
Poland
State/province [51] 0 0
Kotarbinskiego
Country [52] 0 0
Poland
State/province [52] 0 0
Sosnowiec
Country [53] 0 0
Poland
State/province [53] 0 0
Torun
Country [54] 0 0
Poland
State/province [54] 0 0
Wroclaw
Country [55] 0 0
Romania
State/province [55] 0 0
Arges
Country [56] 0 0
Romania
State/province [56] 0 0
Bihor
Country [57] 0 0
Romania
State/province [57] 0 0
Cluj
Country [58] 0 0
Romania
State/province [58] 0 0
Constanta
Country [59] 0 0
Romania
State/province [59] 0 0
Munes
Country [60] 0 0
Romania
State/province [60] 0 0
Sector 4
Country [61] 0 0
Romania
State/province [61] 0 0
Iasi
Country [62] 0 0
Russian Federation
State/province [62] 0 0
Leningrad
Country [63] 0 0
Russian Federation
State/province [63] 0 0
Smolensk region
Country [64] 0 0
Russian Federation
State/province [64] 0 0
Moscow
Country [65] 0 0
Russian Federation
State/province [65] 0 0
Saint-Petersburg
Country [66] 0 0
Russian Federation
State/province [66] 0 0
Samara
Country [67] 0 0
Russian Federation
State/province [67] 0 0
Yaroslavl
Country [68] 0 0
Ukraine
State/province [68] 0 0
Kherson
Country [69] 0 0
Ukraine
State/province [69] 0 0
Dnipropetrovsk
Country [70] 0 0
Ukraine
State/province [70] 0 0
Kharkiv
Country [71] 0 0
Ukraine
State/province [71] 0 0
Kyiv
Country [72] 0 0
Ukraine
State/province [72] 0 0
Lviv
Country [73] 0 0
Ukraine
State/province [73] 0 0
Poltava
Country [74] 0 0
Ukraine
State/province [74] 0 0
Vinnytsia
Country [75] 0 0
United Kingdom
State/province [75] 0 0
Cambridgeshire
Country [76] 0 0
United Kingdom
State/province [76] 0 0
Tyne and Wear
Country [77] 0 0
United Kingdom
State/province [77] 0 0
Exeter
Country [78] 0 0
United Kingdom
State/province [78] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
FORUM Pharmaceuticals Inc
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
Syneos Health
Address [1] 0 0
Country [1] 0 0
Other collaborator category [2] 0 0
Commercial sector/industry
Name [2] 0 0
NeuroCog Trials, Inc.
Address [2] 0 0
Country [2] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to determine if EVP-6124 (an alpha-7 nAChR agonist) enhances the cognitive abilities of subjects with Schizophrenia who are also taking stable antipsychotic therapy.
Trial website
https://clinicaltrials.gov/study/NCT01716975
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT01716975